公开(公告)号：GEP20247670B

公开(公告)日：2024-09-25

申请号：GEAP2020015866

申请日：2020-07-28

Applicant: LES LABORATOIRES SERVIER ,  VERNALIS R&D LTD

Inventor： DAVIDSON JAMES EDWARD PAUL ,  NOVÁK TIBOR ,  PACZAL ATTILA ,  KOTSCHY ANDRÁS ,  STARCK JEROME-BENOIT ,  MURRAY JAMES BROOKE ,  BEDFORD SIMON ,  CHANRION MAÏA ,  COLLAN FRÉDÉRIC ,  DESOS PATRICE ,  DODSWORTH MARK PHILIP ,  DUNKEL PETRA ,  HERNER ANDRÁS ,  MADARÁSZ ZOLTÁN ,  MARAGNO ANA LETICIA ,  MOLNÁR MÁRK ,  NYERGES MIKLOS ,  PARSONS RACHEL JANE ,  RUDASOVÁ MONIKA ,  STROFEK ÁGNES ,  SZIGETI MARIANNA ,  TIMÁRI MÁTYÁS PÁL ,  WEBB PAUL

IPC: A61P35/00 ,  A61K31/428 ,  C07D417/12 ,  C07D417/14

Abstract: Present invention relates to 3,6-diamino-pyrida-zin-3-yl derivatives of formula (I), (I) pharmaceutical compositions containing them, and their usage as pro-apoptotic agents, as inhibitors of Bcl-xL protein activity. s

公开(公告)号：ZA201405101B

公开(公告)日：2015-12-23

申请号：ZA201405101

申请日：2014-07-11

Applicant: LES LABORATORIES SERVIER ,  VERNALIS (R&D) LTD

Inventor： DE NANTEUIL GUILLAUME ,  LE TIRAN ARNAUD ,  HICKMAN JOHN ,  CHAN I-JEN ,  MURRAY JAMES BROOKE ,  HENLIN JEAN-MICHAEL ,  CASARA PATRICK ,  NYERGES MIKLOS ,  DEPIL STEPHANE ,  GENESTE OLIVIER ,  GRAHAM CHRISTOPHER JOHN ,  DAVIDSON JAMES EDWARD PAUL ,  STARCK JEROME-BENOIT ,  LE DIGUARHER THIERRY

Abstract: wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

公开(公告)号：ZA201405418B

公开(公告)日：2020-02-26

申请号：ZA201405418

申请日：2014-07-22

Applicant: LES LABORATORIES SERVIER ,  VERNALIS R&D LTD

Inventor： LE TIRAN ARNAUD ,  STARCK JEROME-BENOIT ,  GUILLOUZIC ANNE-FRANCOISE ,  GENESTE OLIVIER ,  MURRAY JAMES BROOKE ,  LE DIGUARHER THIERRY ,  HENLIN JEAN MICHAEL ,  DE NANTEUIL GUILLAUME ,  DAVIDSON JAMES EDWARD PAUL ,  CHEN I-JEN

Abstract: wherein X, Y, A1, A2, Ra, Rb, Rc, Rd, R3, R4, T and R5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

公开(公告)号：SI4153242T1

公开(公告)日：2024-07-31

申请号：SI202130154

申请日：2021-05-18

Applicant: SERVIER LAB

Inventor： DESOS PATRICE ,  FRANZETTI GEORGES-ALAIN ,  STARCK JEROME-BENOIT ,  KOSTOVA VESELA

IPC: A61K47/00 ,  C07C275/00 ,  C07D207/00 ,  C07D405/00 ,  C07D491/00

公开(公告)号：PH12014000194A1

公开(公告)日：2015-06-29

申请号：PH12014000194

申请日：2014-07-08

Applicant: SERVIER LAB

Inventor： TIRAN ARNAUD LE ,  DIGUARHER THIERRY LE ,  STARCK JEROME-BENOIT ,  HENLIN JEAN-MICHEL ,  GUILLOUZIC ANNE-FRANCOISE ,  NANTEUIL GUILLAME DE ,  GENESTE OLIVIER ,  DAVIDSON JAMES EDWARD PAUL ,  MURRAY JAMES BROOKE ,  CHEN I-JEN

IPC: A61K31/407 ,  A61K31/4353 ,  A61K31/437 ,  C07D471/00 ,  C07D471/04

Abstract: The present invention relates to new phosphate compounds, to a process for their preparation and to pharmaceutical compositions containing them. The compounds of the present invention are new and have very valuable pharmacological and pharmacokinetic characteristics for use in the field of apoptosis and cancerology. Apoptosis, or programmed cell death, is a physiological process that is crucial for embryonic development and maintenance of tissue homeostatis. In addition to being new, the compounds of the present invention have pharmacological and pharmacokinetic properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer, auto-immune diseases and diseases of the immune system.

公开(公告)号：AP201407882A0

公开(公告)日：2014-08-31

申请号：AP201407882

申请日：2013-01-23

Applicant: SERVIER LAB

Inventor： HENLIN JEAN-MICHEL ,  STARCK JEROME-BENOIT ,  DIGUARHER THIERRY LE

IPC: C07D471/00 ,  A61K31/407 ,  A61K31/4353 ,  A61K31/436 ,  A61P35/00 ,  A61P37/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052

CPC classification number: A61K31/5377 ,  A61K31/4725 ,  A61K31/475 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61K45/06 ,  A61N5/10 ,  A61N5/1001 ,  C07D207/30 ,  C07D211/06 ,  C07D211/80 ,  C07D471/00 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

公开(公告)号：SI2151427T1

公开(公告)日：2013-03-29

申请号：SI200930500

申请日：2009-08-04

Applicant: SERVIER LAB

Inventor： BONTEMPELLI PASCAL ,  JALENQUES XAVIER ,  STARCK JEROME-BENOIT ,  SERY JEAN-PIERRE

IPC: C07C231/00 ,  C07C209/00 ,  C07C233/00

公开(公告)号：NZ578827A

公开(公告)日：2010-12-24

申请号：NZ57882709

申请日：2009-08-03

Applicant: SERVIER LAB

Inventor： BONTEMPELLI PASCAL ,  JALENQUES XAVIER ,  STARCK JEROME-BENOIT ,  SERY JEAN-PIERRE

IPC: C07C231/06 ,  C07C235/18

Abstract: Disclosed is a process for the industrial synthesis of the compound of formula (I) characterised in that there is reacted (7-methoxy-1-naphthyl)acetonitrile of formula(II) which is subjected to reduction by hydrogen in the presence of Raney nickel in a medium comprising acetic anhydride in a polar protic medium to yield the compound of formula (I), which is isolated in the form of a solid.

公开(公告)号：ZA200905333B

公开(公告)日：2010-05-26

申请号：ZA200905333

申请日：2009-07-30

Applicant: SERVIER LAB

Inventor： BONTEMPELLI PASCAL ,  JALENQUES XAVIER ,  STARCK JEROME-BENOIT ,  SERY JEAN-PIERRE

IPC: A61K20100101 ,  A61P20100101 ,  C07C20100101

Abstract: Process for industrial synthesis of N-[2-(7-methoxy-naphthalen-1-yl)-ethyl]-acetamide (agomelatine) (I) comprises reacting (7-methoxy-1-naphtyl)acetonitrile, which is subjected to a reduction by hydrogen in the presence of Raney nickel in medium containing acetic anhydride in a polar protic medium to give (I) that is isolated as a solid. ACTIVITY : Antidepressant; Hypnotic; Cardiovascular-Gen.; Gastrointestinal-Gen.; CNS-Gen.; Muscular-Gen.; Eating-Disorders-Gen.; Anorectic. MECHANISM OF ACTION : 5-Hydroxytryptamine 2C receptor antagonist.

公开(公告)号：UA102817C2

公开(公告)日：2013-08-27

申请号：UAA200908226

申请日：2009-08-04

Applicant: SERVIER LAB

Inventor： BONTEMPELLI PASCAL ,  JALENQUES XAVIER ,  STARCK JEROME-BENOIT ,  SERY JEAN-PIERRE

IPC: C07D213/00

Abstract: Способпромышленногосинтезасоединенияформулы (I)(I).